Aspen Grove Capital’s VanEck Pharmaceutical ETF PPH Stock Holding History

Aspen Grove Capital’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.03M	Sell	9,452 -9,224	-49%	-$955K	0.15%	76
2026 Q1	$1.94M	Sell	18,676 -7,533	-29%	-$802K	0.38%	42
2025 Q4	$2.7M	Buy	26,209 +186	+0.7%	+$18.1K	0.47%	37
2025 Q3	$2.35M	Buy	26,023 +179	+0.7%	+$15.7K	0.4%	37
2025 Q2	$2.27M	Buy	25,844 +150	+0.6%	+$13K	0.39%	40
2025 Q1	$2.34M	Hold	25,694	–	–	0.45%	38
2024 Q4	$2.22M	Buy	25,694 +233	+0.9%	+$21.1K	0.47%	37
2024 Q3	$2.42M	Buy	25,461 +100	+0.4%	+$9.5K	0.53%	33
2024 Q2	$2.32M	Buy	25,361 +151	+0.6%	+$13.5K	0.55%	32
2024 Q1	$2.29M	Sell	25,210 -1	-0%	-$88	0.65%	29
2023 Q4	$2.05M	Buy	25,211 +204	+0.8%	+$16K	0.62%	32
2023 Q3	$2M	Buy	25,007 +126	+0.5%	+$10.2K	0.74%	31
2023 Q2	$1.96M	Buy	24,881 +208	+0.8%	+$16.3K	0.63%	31
2023 Q1	$1.92M	Hold	24,673	–	–	0.84%	27
2022 Q4	$1.92M	Buy	+24,673	New	+$1.82M	0.89%	27

Other funds holding PPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JSAM

J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return

AWC

Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return

Aspen Grove Capital's PPH Position: Q2 2026 in Review

Aspen Grove Capital reduced its VanEck Pharmaceutical ETF (PPH) stake by 49% in Q2 2026, selling an estimated $955K and leaving 9,452 shares worth $1.03M. The position accounts for 0.15% of the portfolio, ranked #76.

Aspen Grove Capital first reported a position in PPH in Q4 2022 and has held it in 15 quarters since. The position peaked at $2.7M in Q4 2025. 148 funds tracked by Wall St. Rank hold PPH as of Q2 2026.

Aspen Grove Capital held 9,452 shares of VanEck Pharmaceutical ETF worth $1.03M as of Q2 2026.
Aspen Grove Capital sold 9,224 VanEck Pharmaceutical ETF shares in Q2 2026, an estimated $955K.
VanEck Pharmaceutical ETF made up 0.15% of Aspen Grove Capital's portfolio in Q2 2026, its #76 holding.
Aspen Grove Capital first reported a position in VanEck Pharmaceutical ETF in Q4 2022 and has held it in 15 quarters since.
Aspen Grove Capital's VanEck Pharmaceutical ETF position peaked at $2.7M in Q4 2025.
148 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2026.

Based on Aspen Grove Capital's 13F filing for Q2 2026, filed 14 Aug 2026.